Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Federico Cappuzzo

Showing results (31-40 of 275) with videos related to

Pageof 28
Sort By:
Translational Lung Cancer Research|January 25, 2021
How selecting best upfront therapy for metastatic disease?-Focus on ROS1-rearranged diseaseLorenza Landi, Federico Cappuzzo
Lung Cancer (Auckland, N.Z.)|February 18, 2017
Profile of bavituximab and its potential in the treatment of non-small-cell lung cancerIrene Stasi, Federico Cappuzzo
The Lancet. Oncology|September 6, 2019
Chemoimmunotherapy for stage IV non-small-cell lung cancer - Authors' replyFederico Cappuzzo, Howard West
I Supplementi Di Tumori : Official Journal of Societa Italiana Di Cancerologia ... [Et Al.]|November 6, 2002
New platinum derivatives in advanced non-small cell lung cancerLucio Crinò, Federico Cappuzzo
Seminars in Oncology|July 3, 2002
Present and future treatment of advanced non-small cell lung cancerLucio Crinò, Federico Cappuzzo
Targeted Oncology|May 6, 2010
Impact of biomarkers on non-small cell lung cancer treatmentLuca Toschi, Federico Cappuzzo
Expert Opinion on Pharmacotherapy|September 16, 2014
Pharmacotherapy targeting the EGFR oncogene in NSCLCLorenza Landi, Federico Cappuzzo
Translational Respiratory Medicine|December 16, 2014
Second generation tyrosine kinase inhibitors for the treatment of metastatic non-small-cell lung cancerIrene Stasi, Federico Cappuzzo
Translational Lung Cancer Research|March 26, 2015
Targeting MET in NSCLC: looking for a needle in a haystackLorenza Landi, Federico Cappuzzo
JAMA Oncology|September 18, 2025
Neoadjuvant Chemoimmunotherapy in Stage III Non-Small Cell Lung Cancer-ReplyEdoardo Garbo, Biagio Ricciuti, Federico Cappuzzo
Pageof 28

Showing results (31-40 of 275) with videos related to

Sort By:
Pageof 28
Translational Lung Cancer Research|January 25, 2021
How selecting best upfront therapy for metastatic disease?-Focus on ROS1-rearranged diseaseLorenza Landi, Federico Cappuzzo
Lung Cancer (Auckland, N.Z.)|February 18, 2017
Profile of bavituximab and its potential in the treatment of non-small-cell lung cancerIrene Stasi, Federico Cappuzzo
The Lancet. Oncology|September 6, 2019
Chemoimmunotherapy for stage IV non-small-cell lung cancer - Authors' replyFederico Cappuzzo, Howard West
I Supplementi Di Tumori : Official Journal of Societa Italiana Di Cancerologia ... [Et Al.]|November 6, 2002
New platinum derivatives in advanced non-small cell lung cancerLucio Crinò, Federico Cappuzzo
Seminars in Oncology|July 3, 2002
Present and future treatment of advanced non-small cell lung cancerLucio Crinò, Federico Cappuzzo
Targeted Oncology|May 6, 2010
Impact of biomarkers on non-small cell lung cancer treatmentLuca Toschi, Federico Cappuzzo
Expert Opinion on Pharmacotherapy|September 16, 2014
Pharmacotherapy targeting the EGFR oncogene in NSCLCLorenza Landi, Federico Cappuzzo
Translational Respiratory Medicine|December 16, 2014
Second generation tyrosine kinase inhibitors for the treatment of metastatic non-small-cell lung cancerIrene Stasi, Federico Cappuzzo
Translational Lung Cancer Research|March 26, 2015
Targeting MET in NSCLC: looking for a needle in a haystackLorenza Landi, Federico Cappuzzo
JAMA Oncology|September 18, 2025
Neoadjuvant Chemoimmunotherapy in Stage III Non-Small Cell Lung Cancer-ReplyEdoardo Garbo, Biagio Ricciuti, Federico Cappuzzo
Pageof 28